BiotechTube

Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankle Sprain

Conditions

Ankle Sprain

Trial Timeline

Nov 1, 2007 → Jul 1, 2008

NCT ID
NCT00573768

About Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / Placebo

Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / Placebo is a phase 2 stage product being developed by Novartis for Ankle Sprain. The current trial status is completed. This product is registered under clinical trial identifier NCT00573768. Target conditions include Ankle Sprain.

What happened to similar drugs?

3 of 7 similar drugs in Ankle Sprain were approved

Approved (3) Terminated (0) Active (4)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅diclofenac potassium 25 mg tablet + placeboNovartisApproved
🔄Diclofenac SodiumNovartisPhase 3
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
🔄Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
✅Non-selective NSAIDS + CelecoxibPfizerApproved
🔄Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00573768Phase 2Completed

Competing Products

7 competing products in Ankle Sprain

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
diclofenac potassium 25 mg tablet + placeboNovartisApproved
43
Diclofenac SodiumNovartisPhase 3
40
diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
40
Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
40
Non-selective NSAIDS + CelecoxibPfizerApproved
43
Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3
40